Overview

RDEA3170 Monotherapy in Subjects With Gout

Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This study will assess the serum uric acid lowering effects and safety of 3 dose levels of RDEA3170 compared to placebo in subjects with gout.
Phase:
Phase 2
Details
Lead Sponsor:
Ardea Biosciences, Inc.
Treatments:
Verinurad